- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Robert Gabbay Talks About Adding Finenerone as a Recommended Drug in New ADA Guidelines
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenon) as a recommended drug for kidney disease prevention.
Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), breaks down the reasoning behind the organization's decision to add Bayer's Kerendia (finerenone) as a recommended drug for kidney disease prevention.
Transcript
What went into the ADA’s decision to add a recommendation for the use of Bayer’s Kerendia (finerenone) for preventing CKD progression and cardiovascular events?
Each year, as we develop the standards of care, we review all of the scientific and medical literature the year before. One of the things that really jumped out was the availability of new treatments to prevent progression of chronic kidney disease and congestive heart failure. Finerenone, a newly approved drug, has had some wonderful evidence and randomized controlled trials to do both of those things. And it was important that we update the standards so that clinicians could understand how they could use this new treatment modality.
Weight Fluctuation Threatens Kidney Health in Type 1 Diabetes
February 4th 2025Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling) in the general population, which interested investigators in potential links between these weight fluctuations and increased risk of renal events among a population with type 1 diabetes.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Transforming Kidney Care: Policy, Risk Stratification, and Collaborative Models
December 12th 2024Experts at a recent Institute for Value-Based Medicine event emphasized the importance of early intervention, policy innovation, and proactive collaboration to transform the management of kidney disease and optimize patient outcomes.
Read More
